Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161008 | 0.85 | MAPK8 (0.49) | KDM4ELMNAMAPK8CYP17A1CNR1 | |
| SCHEMBL10130798 | 0.82 | TRPV3 (0.39) | SMN1; SMN2CNR1ALDH1A1TRPV3FBP1 | |
| SCHEMBL14403920 | 0.79 | KDM4E (0.51) | KDM4ELMNASMN1; SMN2MAPK8CYP17A1 | |
| SCHEMBL10130760 | 0.75 | IDH1 (0.46) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL10130623 | 0.75 | CCR1 (0.47) | KDM4EFAAHALDH1A1HSD17B10ADORA2A | |
| SCHEMBL10130800 | 0.71 | PDE10A (0.39) | — | |
| SCHEMBL10130788 | 0.71 | DYRK1A (0.35) | CNR1ALDH1A1TRPV3HPGDDYRK1A | |
| SCHEMBL10130820 | 0.70 | IDH1 (0.40) | ALDH1A1ADORA2ATRPV3FBP1HPGD | |
| SCHEMBL821844 | 0.70 | KDM4E (0.71) | KDM4ELMNASMN1; SMN2MAPK8ALDH1A1 | |
| SCHEMBL10130562 | 0.67 | KDM4E (0.58) | KDM4ELMNASMN1; SMN2CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | KDM4E 56/4885LMNA 4270/4885SMN1; SMN2 4275/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KDM4E 56/4885LMNA 4270/4885SMN1; SMN2 4275/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KDM4E 56/4885LMNA 4270/4885SMN1; SMN2 4275/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | KDM4E 1038/4885LMNA 4361/4885SMN1; SMN2 2894/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | KDM4E 56/4885LMNA 4270/4885SMN1; SMN2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.